Premium
Mitochondrial Protonophores For Treatment of NAFLD/NASH and Type 2 Diabetes
Author(s) -
Shulman Gerald I
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.257.2
Subject(s) - insulin resistance , type 2 diabetes , lipotoxicity , steatohepatitis , fatty liver , endocrinology , adipose tissue , skeletal muscle , medicine , steatosis , biology , diabetes mellitus , disease
This presentation will focus on the cellular mechanisms of insulin resistance in humans and the role of ectopic lipid deposits in liver and skeletal muscle in its pathogenesis. Specifically this talk will review recent studies that have implicated diacylglycerol activation of novel PKCs as the molecular trigger for lipid‐induced insulin resistance in these tissues. This talk will also review recent studies that identify the link between adipose tissue inflammation and increased rates of hepatic gluconeogenesis in type 2 diabetes as well as novel mitochondrial protonophore therapies that reverse type 2 diabetes and non alcoholic steatohepatitis through promotion of subtle increases in hepatic mitochondrial inefficiency and reductions in ectopic lipid deposition in liver and skeletal muscle. Support or Funding Information This work was supported by grants from NIDDK/NIH: R01 DK‐40936, R01 DK‐49230, the American Diabetes Association and HHMI.